NanoGroup S.A.

NNG

PLNNGRP00011

Biotechnology & Medical Research

Delayed Warsaw S.E. Other stock markets 11:02:39 14/05/2024 BST			5-day change	1st Jan Change
1.01 ^PLN	-0.98%		-1.46%	+8.84%

2023	NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	NanoGroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

NanoGroup Seeks Acquisitions

October 17, 2017 at 05:00 am

NanoGroup S.A is seeking acquisitions. NanoGroup is negotiating the acquisition of two more companies.

Latest news about NanoGroup S.A.

NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-06	CI
NanoGroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	29/09/23	CI
NanoGroup S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	19/05/23	CI
NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	29/11/22	CI
NanoGroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	19/09/22	CI
NanoGroup S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/05/22	CI
NanoGroup S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	29/04/22	CI
NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/11/21	CI
Nanogroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	04/10/21	CI
Nanogroup S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/05/21	CI
An undisclosed buyer acquired 35.24% stake in NanoGroup S.A. from GPV I Inwestycje Sp. z o.o.	18/07/18	CI
NanoGroup S.A. has completed an IPO in the amount of PLN 4.18 million.	21/11/17	CI
NanoGroup Seeks Acquisitions	25/10/17	CI
NanoGroup Seeks Acquisition	20/10/17	CI
NanoGroup Seeks Acquisitions	17/10/17	CI
NanoGroup S.A. has filed an IPO in the amount of PLN 45 million.	13/10/17	CI

Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOGROUP S.A.	+8.84%	5.16M
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+44.87%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B